GILEAD SCIENCES, INC. (GILD)

symbol lookup

Follow GILD via My Validea and receive an email alert whenever any of our strategies changes its rating.

Get Started
Score: 96/100
Analysis based upon 11/17/2017 closing price.
Latest Close: $72.44 Market Cap ($ mil): $94,601 Sector: Healthcare Industry: Biotechnology & Drugs Debt/Equity: 1.18
PE Ratio: 8.2 Price/Sales: 3.4 Price/Book: 3.8 Yield: 2.9% Return on Equity: 55.6%
52 Week High: $86.27 52 Week Low: $63.76 Relative Strength: 35 LT EPS Growth: 57.9% LT Sales Growth: 33.8%
Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Report Card - Patient Investor

Guru Criteria: Warren Buffett  
EARNINGS PREDICTABILITY:PASS
DEBT SERVICE:PASS
RETURN ON EQUITY:PASS
RETURN ON TOTAL CAPITAL:PASS
FREE CASH FLOW:PASS
USE OF RETAINED EARNINGS:PASS
SHARE REPURCHASE:PASS
INITIAL RATE OF RETURN:PASS
EXPECTED RETURN:PASS

Detailed Analysis

Get a full analysis of GILD using this and 11 other strategies of investment legends.

Start Your Free Trial